首页> 美国卫生研究院文献>Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis >Nonuremic Indication for Peritoneal Dialysis for Refractory Heart Failure in Cardiorenal Syndrome Type II: Review and Perspective
【2h】

Nonuremic Indication for Peritoneal Dialysis for Refractory Heart Failure in Cardiorenal Syndrome Type II: Review and Perspective

机译:非尿毒症适应症腹膜透析治疗II型心肾综合征难治性心力衰竭的回顾与展望

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cardiorenal syndrome (CRS) type II is a serious condition in which chronic cardiac abnormalities cause worsening kidney function, leading to permanent chronic kidney damage. Management of CRS type II coupled with diuretic-resistant congestive heart failure (CHF) has been an issue of dispute. However, since the early 1990s, reports indicating the clinical usefulness of peritoneal dialysis (PD) as maintenance therapy for intractable CHF in this population have been accumulating. The present manuscript reviews the mechanisms by which kidney dysfunction develops within CHF, and then examines recent experiences of PD as chronic supportive therapy for intractable CRS type II, reviews the contributing mechanisms, and discusses the rationale for using PD as a new therapeutic approach in the nonuremic setting of CHF.
机译:II型心肾综合征(CRS)是一种严重疾病,其中慢性心脏异常会导致肾脏功能恶化,从而导致永久性慢性肾脏损害。 II型CRS的治疗以及利尿剂抵抗性充血性心力衰竭(CHF)的治疗一直是一个争论的问题。然而,自1990年代初以来,越来越多的报道表明腹膜透析(PD)作为该人群顽固性CHF维持治疗的临床有用性。本手稿回顾了CHF内肾脏功能障碍发展的机制,然后回顾了PD作为II型顽固性CRS的慢性支持疗法的最新经验,回顾了其作用机制,并讨论了将PD作为一种新的治疗方法的理论基础。 CHF的非尿毒症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号